Takeda withdraws Actos in France as it awaits EMA decision
This article was originally published in Scrip
Takeda is withdrawing its pioglitazone-containing products Actos and Competact in France, at the request of Afssaps, the French health regulatory authority. This follows Afssaps' recent decision to suspend the use of pioglitazone containing products for the treatment of type 2 diabetes. The same decision was taken shortly after by the German authorities, although the Japanese drug-maker has yet to announce a similar move in Germany.